입양 세포 전송: 기증자 쥐 비장 세포를 숙주 쥐에 도입 후 FACS를 통한 성공 평가
English
Share
Overview
출처: 뮤니에 실베인1,2,3,퍼셰 티보1,2,3,소피 노볼트4,레이첼 골럽1,2,3
1 림프포포에이시스, 면역학학과, 파스퇴르 연구소, 파리, 프랑스
2 INSERM U1223, 파리, 프랑스
3 유니버시테 파리 디드로, 소르본 파리 시테, 셀룰레 파스퇴르, 파리, 프랑스
4 흐름 세포측정플리트에서, 세포측정및 바이오마커 UtechS, 번역 과학 센터, 파스퇴르 연구소, 파리, 프랑스
입양 세포 전달은 질병을 치료하거나 혈액 마비증과 같은 생물학적 과정을 연구하기 위해 환자 또는 연구 유기체로 세포를 도입하는 방법입니다. 입양 전송의 목적은 다양합니다. 그것은 기본 생물학뿐만 아니라 의학에서 사용할 수 있습니다 (1, 2). 마우스 모델에서, 전송된 세포의 이동 및 분포는 추적 시스템(세포 표면 마커, CFSE에 의한 염색 등)에 의해 연구되고 그 다음에 선행될 수 있다. 마우스 모형에 암 연구 결과에서는, 특정 세포 인구의 전송은 종양에 대하여 실험적인 처리로 이용될 수 있습니다. 이 기술에 대한 또 다른 예는 심한 면역 결핍 표현형을 가진 조사 마우스 또는 마우스에 골수 세포의 전송에 의해 키메라 마우스의 생성이다. 이 마우스 모형은 예를 들면 특정 세포 인구에 유전자 삭제의 충격을 평가하기 위하여 이용될 수 있습니다. 뼈 차용 세포의 전송은 또한 인간의 치료에 사용됩니다. 환자가 암 치료의 경우에 조사될 때, 골수의 입양 전송은 면역 계통 재구성을 허용합니다.
이 기술의 첫 번째 단계는 관심의 세포 인구를 얻는 것입니다. 이 인구를 격리하기 위해 선택한 기술은 대상 인구의 특이성 수준에 따라 달라집니다. 선택의 가장 큰 수준은 장기에 존재하는 모든 세포 집단이 취해지는 전체 기관입니다. 보다 정밀한 방법은 표적 세포 집단의 선택이며, 종종 하나의 세포 표면 마커에 의해 선택된다. 이 경우 셀을 정렬하는 이상적인 방법은 자기 정렬입니다. 마지막으로, 가장 엄격한 수준은 매우 특정 세포 집단을 정렬하는 여러 세포 표면 마커에 의해 세포의 선택입니다. 흐름 세포 분석 정렬은 이 선택 수준에 가장 인기 있는 방법입니다. 관심 의 인구가 얻어지면 호스트로 전송 할 수 있습니다. 입양 전송 전에 호스트와 기증자 사이의 호환성을 보장하는 것이 필수적입니다. 실제로, 전송 목표에 관계없이 호환성은 세포 거부없이 호스트에 의해 세포 채택을 보장하기 위해 중요합니다.
본 실습에서, CD45.2 마우스에서 비장세포를 CD45.1 Ragγc 마우스(림프구 부족)로 이송하여 채택세포 전달 기술을 입증하고 4일 후 유동 세포측정법을 사용하여 비장세포 전달을 확인한다(그림 1참조).
그림 1: 입양 전송의 회로도 표현. (1) 비장세포는 CD45.2 마우스로부터 분리되고 (2) CD45.1 Ragγc 마우스로 전송되며, 제어 마우스는 PBS만으로 주입된다. (3) 입양 전달 후 4일, 비장세포는 마우스로부터 회수되고 (4) 혈류 세포측정에 의해 분석된다. 이 그림의 더 큰 버전을 보려면 여기를 클릭하십시오.
Procedure
Results
Ragγc mice have an altered immune system composition, mainly lacking lymphocytes. Adoptive transfer of splenocytes allows introduction of lacking population such as T and B cells. Our staining included cell surface markers CD45.1 and CD45.2 to distinguish host and donor cells respectively (Figure 2A). It also included other cell surface marker to highlight cell populations absent in Ragγc mice, such as CD4 T cells (Figure 2B). As expected, control mouse did not have CD45.2-positive cells (Figure 2B, top panels) and transferred mouse did (Figure 2B, bottom panels, 71.2% of total cells). We could also specifically detect CD4 T cells within transferred cells (22.1% of CD45.2 cells).
Figure 2: Representative results of adoptive transfer. (A) Histograms of CD45.2 cells from mice injected with PBS (control group) (dashed) and mice injected with CD45.2 splenocytes (test group) (solid line). (B) Gating strategy of CD45.2-positive cells in control mice injected with PBS (top panels) and mice injected with CD45.2 splenocytes (bottom panels). Donor and host cells are distinguished using cell surface markers (CD45.1, CD45.2), then CD45.2-positive cell population are characterized (CD3, CD4). Please click here to view a larger version of this figure.
Applications and Summary
Adoptive transfer is a translational technique in different fields of science, with applications in medicine. This technique can be used to study cell migration and tropism or incidence of protein deficiency in specific cell populations. In the last case, different technologies can be used, especially GMO mice where specific cell populations are intrinsically deficient. However, genetic construction to obtain GMO mice can be a very complex and long process. In this case, adoptive transfer of deficient cell population is easier and faster.
Adoptive transfers have direct applications in medicine. For instance, bone marrow grafts in irradiated patients during cancer therapy are used to reconstitute the immune system. Recently, other applications of adoptive transfer have been used in the medical field. Artificial T cells (called CAR T cell) are designed to recognize and eliminate some cancers. In addition, these engineered cells are built to dampen rejection risk by the host. Transfer of CAR T cells is currently tested in clinical trials.
References
- Restifo, N. P., Dudley, M. E. and Rosenberg., S. A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature reviews. Immunology, 12 (4): 269-281, (2012).
- Bonini, C., and Mondino, A. Adoptive T-cell therapy for cancer: The era of engineered T cells. European journal of immunology, 45 (9): 2457-69, (2015).
Transcript
Adoptive cell transfer is a method for introducing cells of interest into an organism. It is a powerful technique to study various biological mechanisms, including the action of specific classes of immune cells. In addition, adoptive transfer is a promising novel treatment for numerous conditions, such as those requiring bone marrow transplants or cancer treatments where a patient’s own T-cells can be extracted, altered to recognize and destroy the cancerous cells, and then returned to the body to fight tumors.
In the laboratory, animal models are often used to study adoptive transfer. For example, CD45.1 Rag gamma-c knockout mice lack fundamental receptors for many cytokines, which are essential for normal differentiation of hematopoietic stem cells into lymphocytes. As a result, the knockout mice have a compromised lymphocyte development and do not have natural killer, or NK, cells, T-cells, or B-cells.
Adoptive transfer can be used to introduce the missing immune cells into these compromised mice, by first harvesting donor mouse tissue containing high concentrations of immune cells, such as the spleen. The tissue is then dissociated and a variety of spleen cells, including the immune cells, are isolated. Next, unwanted erythrocytes, or red blood cells, can be lysed via the addition of ammonium chloride potassium lysing buffer and the remaining white blood cells, or splenocytes, are then separated from the cell debris using centrifugation.
Finally, the purified splenocytes are injected into the immunocompromised mice, facilitating detailed studies of these cells’ functions. Several days later, the success of the adoptive immune cell transfer can be confirmed by first isolating and preparing the host splenoncytes in the same manner as the donor tissue. Then, these cells are stained using labeled antibodies against the donor immune cell markers so that they can be verified and sorted using FACS.
To begin, put on laboratory gloves and the appropriate protective equipment. Next, wash a pair of forceps and dissecting scissors first with a detergent and then with 70% ethanol and then dry them with a clean paper towel. Prepare 50 milliliters of Hank’s Balanced Salt Solution, or HBSS, with 2% Fetal Calf Serum, or FCS, by combining one milliliter of FCS with 49 milliliters of HBSS in a 50 milliliter tube. Mix by gently pipetting the solution up and down approximately 10 times.
Dissect the euthanized mouse and remove its spleen as demonstrated in the JoVE video protocol FACS technology for splenic B lymphocytes separation. To isolate immune cells, first place the spleen on a 40 micrometer cell strainer in a petri dish. Crush the spleen with a plunger to dissociate it into the dish. Recover the adhered cells by rinsing the plunger and the strainer with 1 milliliter of HBSS 2% FCS. Then, pipette the dissociated spleen and fluid from the petri dish into a 50 milliliter centrifuge tube. Wash the petri dish with 5 milliliters of HBSS 2% FCS and transfer the fluid to the 15 milliliter tube.
Centrifuge the tube at 370 times g for seven minutes at 10 degrees Celsius and then retrieve the tube carefully so as not to disturb the pellet. Now, remove the supernatant without disturbing the pellet and discard the liquid in an appropriate waste container. Then, add two milliliters of ammonium chloride potassium lysing buffer to the centrifuge tube and pipette up and down to resuspend the pellet and lyse the erythrocytes. Wait for two minutes and then add HBSS 2% FCS to the resuspended pellet to obtain a total value of 14 milliliters. Repeat the centrifugation. Retrieve the tube carefully and discard the supernatant. Then, resuspend the pellet in 5 milliliters HBSS 2% FCS by pipetting up and down. Next, count the cells in suspension. Add five microliters of trypan blue to five microliters of cell suspension and mix well by pipetting. Then, gently deposit a five microliter drop of diluted cell suspension between the cover glass and the Malassez slide. With the microscope set to 40X magnification, count the number of cells. Adjust the cell concentration to 10 to the seven cells per milliliter by adding the appropriate volume of HBSS 2% FCS.
To begin the adoptive transfer, transfer two milliliters of the cell suspension to a five milliliter collection tube. Centrifuge the tube at 370 times g for seven minutes at 10 degrees Celsius and then discard the supernatant. Next, resuspend the pellet in two milliliters of phosphate buffered saline and centrifuge the tube at 370 times g for seven minutes at 10 degrees Celsius. Discard the supernatant. Then, resuspend the pellet in 200 microliters of phosphate buffered saline. Using a 0.5 milliliter syringe with a 29-gauge needle, inject 200 microliters of cell suspension into the experimental mouse intravenously into the retro-orbital blood sinus.
Four days after the adoptive transfer, euthanize the mice and remove the spleens. Then, harvest the immune cells as described in section three. Next, transfer 100 microliters of cell suspension from each mouse into two FACS tubes labeled control and transferred. Centrifuge the tubes at 370 times g for seven minutes at 10 degrees Celsius and then discard the supernatants. Now, prepare a mix containing the four antibodies at the dilution listed in table one. Add 100 microliters of the mix to each tube and then incubate for 20 minutes on ice in the dark. Next, add one milliliter of HBSS 2% FCS to each tube and then centrifuge the tubes at 370 times g for three minutes at 10 degrees Celsius. Discard the supernatants and then resuspend the pellets in 200 microliters of HBSS 2% FCS. Transfer the resuspended cells to new labeled FACS tubes. Now, use flow cytometry as shown in the FACS protocol to evaluate the presence of CD45. 2 positive lymphocytes.
Now, we will determine the presence CD45.2 lymphocytes that were isolated from the CD45. 1 host spleen. To start, double click on the FlowJo icon and drag the files for each tube in the all sample window. Then, double click on the transferred file to display the cells recorded from that sample on a dot plot that displays forward scatter FSCA on the x-axis and side scatter SSCA on the y-axis. Click on polygon to circle the lymphocyte populations. A new subpopulation identification window appears. Click on OK. Now, set the y-axis to FSC-W and the x-axis to FSC-A. Select the single cell population with the polygon tool as previously demonstrated.
Next, double click on the circled population to create a new window for the selected cells. In the new window, select CD45.2 on the Y and CD45.1 on the X. Click on the T icon and customize the axis to enlarge the plot. Next, click on polygon to circle the CD45.2 positive cells. In the subpopulation identification window, name your cell population transferred cells and click OK. In the same window, click on rectangle to select the CD45.2 negative cells. In the subpopulation identification window, name your cell population host cells and click OK. Next, double click on the CD45.2 circled population, transferred population, to create a new window for the selected cells. In the new window, select CD3 on the Y and CD4 on the X.
Next, click on polygon to circle the CD4 CD3 positive cells. In this subpopulation identification window, name your cell population transferred CD4 cells. Then, repeat the previous analysis steps with the control mouse file. Finally, to visualize your cell populations, click on Layout Editor. Drag the transferred cells and the transferred CD4 cells population from transferred and control files into the Layout Editor tab. A dot plot representing CD45.2 positive cells and CD4 lymphocytes will appear. CD45. 2 transferred cells should only appear in the transferred mouse dot plot.